The Filing Desk

Allarity Therapeutics vs Scienture

Allarity Therapeutics ALLR · Scienture SCNX · Pharmaceuticals

Scienture reported revenue of $0 million in fiscal 2025, 1.3 times Allarity Therapeutics' $0 million in fiscal 2025. Allarity Therapeutics had an operating margin of -3939.1%, against -9867.9% at Scienture.

Side by side

Allarity TherapeuticsScienture
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$0M$0M
Revenue growth—215.9%
Revenue growth a year, last 5 years—−52.8%
Gross margin—76.8%
Operating margin−3,939.1%−9,867.9%
Net margin−3,509.7%−9,618.0%
Free cash flow−$15M—
Free cash flow margin−4,633.8%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$3M$0M
Change in diluted share count794.8%320.1%
Last close$0.86$2.44
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Allarity TherapeuticsScienture
Operating margin
Percent of revenue
Allarity TherapeuticsScienture
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Allarity TherapeuticsScienture

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Allarity Therapeutics and Scienture pages.